High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: Final results of the French multicentric randomised CMA/PEGASE 04 protocol

European Journal of Cancer

Volumn 41, Issue 1, 2005, Pages 71-80

  Lotz, Jean Pierre ^a,b,c,d,e,f   Curé, Hervé ^b,c,d,e   Janvier, Maud ^b,c,d,e   Asselain, Bernard ^b,c,d,e   Morvan, François ^b,c,d,e   Legros, Michel ^b,c,d,e   Audhuy, Bruno ^b,c   Biron, Pierre ^b,c,d,e   Guillemot, Maryse ^e   Goubet, Jocelyne ^b,c   Laadem, Abderrahmane ^a   Cailliot, Christian ^b,c   Maignan, Christine Le ^a   Delozier, Thierry ^b,c   Glaisner, Sylvie ^b,c   Maraninchi, Dominique ^b,c,d,e   Roché, Henri ^b,c,d,e   Gisselbrecht, Christian ^a,b,c,d,e  

^a SAINT LOUIS HOSPITAL   (France)

^b 20 24 R Pont St Pierre 31052 T   (France)

^c FNCLCC   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e BLUESTAT   (France)

^f HÔPITAL TENON   (France)

Author keywords

High dose chemotherapy; Metastatic breast cancer; Survival; Time to progression

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; MELPHALAN; MITOXANTRONE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAINTENANCE THERAPY; METASTASIS; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MIDDLE AGED; MITOXANTRONE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 19944401062     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.09.006     Document Type: Article

References (30)

1. S. Flamm Honig Hormonal therapy and chemotherapy (for metastatic disease) J.R. Harris M.E. Lippman M. Morrow S. Hellman Diseases of the Breast 1996 Lippincott-Raven Philadelphia, PA 669 734
2. W. Hryniuk, and H. Bush The importance of dose intensity in chemotherapy of metastatic breast cancer J Clin Oncol 2 1984 1281 1288
3. I.C. Henderson, D.F. Hayes, and R. Gelman Dose-response in the treatment of breast cancer: a critical review J Clin Oncol 6 1988 1501 1515
4. K.H. Antman, P.A. Rowlings, and W.P. Vaughan High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 15 1997 1870 1879
5. A. Gratwohl, J. Passweg, and H. Baldomero European group for blood and marrow transplantation: blood and marrow activity in Europe in 1996 Bone Marrow Transpl 22 1998 227 240
6. S. Rodenhuis, A. Westermann, and M.J. Holtkamp Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer J Clin Oncol 14 1996 1473 1483
7. R. Ghalie, C.R. Richman, and S.S. Adler Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation J Clin Oncol 12 1994 342 346
8. L.J. Ayash, C. Wheeler, and D. Fairclough Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer J Clin Oncol 13 1995 2043 2049
9. E.R. Broun, R. Sridhara, and G.W. Sledge Tandem autotransplantation for the treatment of metastatic breast cancer J Clin Oncol 13 1995 2050 2055
10. H.D. Bitran, B. Samuels, and L. Llein Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer Bone Marrow Transpl 17 1996 157 162
11. C. Gisselbrecht, J.M. Extra, and J.P. Lotz Cyclophosphamide/mitoxantrone/ melphalan (CMA) regimen prior to autologous bone marrow transplantation in metastatic breast cancer Bone Marrow Transpl 18 1994 857 863
12. E.L. Kaplan, and P. Meier Nonparametric estimation for incomplete observations J Am Stat Assoc 53 1958 457 481
13. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
14. L.S. Freedman Tables of the number of patients required in clinical trials using the log-rank test Stat med 1 1982 121 129
15. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winckler Reporting results of cancer treatment Cancer 47 1981 207 214
16. J. Bergh Dose intensity in patients with metastatic breast cancer - time for a novel thoughts Ann Oncol 8 1997 109 110
17. F.R. Dunphy, G. Spitzer, and J.E. Fornoff Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support Cancer 73 1994 2157 2167
18. F.R. Dunphy, G. Spitzer, and A.U. Buzdar Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support J Clin Oncol 8 1990 1207 1216
19. W.P. Peters, E.J. Shpall, and R.B. Jones High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol 6 1988 1367 1376
20. D.M. Eddy High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer J Clin Oncol 10 1992 657 670
21. Z.U. Rahman, D.K. Frye, and A.U. Buzdar Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer J Clin Oncol 15 1997 3171 3177
22. A. Schneeweiss, M. Hensel, and P. Sinn Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose Ann Oncol 13 2002 650 652
23. W.P. Peters, R.B. Jones, and J. Vredenburgh A large prospective randomized trial of high dose combination alkylating agents (CPB) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM) Proc Am Soc Clin Oncol 15 1996 121 (abstract 149)
24. E.A. Stadtmauer, A. O'Neill, and L.J. Goldstein Phase III randomized of high-dose chemotherapy (HD-CT) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate, and 5-Fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional chemotherapy: the Philadelphia Intergroup Study (PBT-1) New Eng J Med 342 2000 1069 1076
25. M. Crump, S. Gluck, and D. Stewart A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (AHPCT) compared to standard chemotherapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) Clinical Trials Group study Proc Am Soc Clin Oncol 20 2001 21a (abstract 82)
26. P. Biron, M. Durand, and H. Roché High dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC100 compared to 4 FEC100 alone allowed a better disease free survival in first line chemotherapy metastatic breast cancer Proc Am Soc Clin Oncol 21 2002 42a (abstract 167)
27. J. Crown, L. Pey, and M. Lind Superiority of tandem high-dose chemotherapy (HDC) versus optimised conventionaly-dosed chemotherapy (CDC) in patients-pts) with metastatic breast cancer (MBC): the International Randomized Breast Cancer Dose Intensity Study (IBDIS 1) Proc Am Soc Clin Oncol 22 2003 23 (abstract 88)
28. M. Hensel, A.D. Ho, and G. Bastert Prognostic markers for survival after high-dose chemotherapy with autologous stem-cell transplantation for breast cancer Ann Oncol 14 2003 341
29. S. Rodenhuis, M. Bontenbal, and L.V. Beex High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer N Engl J Med 349 2003 7 16
30. P.A. Greenberg, G.N. Hortobagyi, and T.L. Smith Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 14 1996 2197 2205